Stay updated with breaking news from Nasdaq Bcli. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Rating)’s share price crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $2.20 and traded as high as $3.16. Brainstorm Cell Therapeutics shares last traded at $2.78, with a volume of 440,422 shares trading […]
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Rating) was the recipient of a large growth in short interest in March. As of March 31st, there was short interest totalling 3,100,000 shares, a growth of 29.7% from the March 15th total of 2,390,000 shares. Currently, 11.0% of the company’s stock are sold short. Based on an […]
Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Rating) announced its quarterly earnings data on Thursday. The biotechnology company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.04, Yahoo Finance reports. During the same quarter in the prior year, the company earned ($0.17) EPS. Brainstorm Cell Therapeutics Stock Performance BCLI traded up […]
Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Rating) released its earnings results on Thursday. The biotechnology company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.04, Yahoo Finance reports. During the same period in the prior year, the firm posted ($0.17) earnings per share. Brainstorm Cell Therapeutics Trading Up 32.0 % […]
StockNews.com cut shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Rating) from a hold rating to a sell rating in a research note released on Sunday morning. Brainstorm Cell Therapeutics Price Performance BCLI opened at $2.44 on Friday. Brainstorm Cell Therapeutics has a fifty-two week low of $1.09 and a fifty-two week high of $4.70. […]